Table 5.
Lipid outcomes in the Jones study24
| Fenofibric acid | Rosuvastatin 10 mg | Fenofibric acid + rosuvastatin 10 mg | Rosuvastatin 20 mg | Fenofibric acid + rosuvastatin 20 mg | Rosuvastatin 40 mg | |
|---|---|---|---|---|---|---|
| HDL-C | n = 220 | n = 239 | n = 224 | n = 236 | n = 225 | n = 127 |
| Baseline mean (mg/dL) | 38.5 | 38.2 | 38.5 | 38.5 | 38.0 | 37.4 |
| Final mean (mg/dL) | 43.9 | 41.0 | 45.7 | 41.6 | 44.9 | 40.6 |
| Mean percent change from baseline (%) | 15.0 | 8.5 | 20.3 (P < 0.001a) | 10.3 | 19.0 (P < 0.001b) | 9.3 |
| TG | n = 242 | n = 252 | n = 252 | n = 255 | n = 249 | n = 127 |
| Baseline mean (mg/dL) | 267.4 | 295.9 | 282.8 | 292.8 | 292.9 | 282.4 |
| Final mean (mg/dL) | 167.9 | 202.6 | 141.6 | 196.1 | 145.9 | 177.1 |
| Mean percent change from baseline (%) | −32.6 | −24.4 | −47.1 (P < 0.001a) | − 25.6 | −42.9 (P < 0.001b) | −32.1 |
| LDL-C | n = 223 | n = 243 | n = 231 | n = 238 | n = 230 | n = 127 |
| Baseline mean (mg/dL) | 155.8 | 152.2 | 152.7 | 154.4 | 155.5d | 153.2 |
| Final mean (mg/dL) | 142.3 | 93.8 | 94.8 | 83.1 | 91.8 | 74.6 |
| Mean percent change from baseline (%) | −6.5 | −38 | −37.2 (P < 0.001c) | −45.0 | −38.8 (P < 0.001d) | −50.6 |
| Non-HDL-C | n = 220 | n = 238 | n = 224 | n = 236 | n = 225 | n = 115 |
| Baseline mean (mg/dL) | 218.7 | 218.7 | 217.7 | 220.9 | 220.8 | 219.0 |
| Final mean (mg/dL) | 176.5 | 130.9 | 119.9 | 118.6 | 118.5 | 105.9 |
| Mean percent change from baseline (%) | −18.5 | −39.8 | −44.7 (P < 0.001a,c) | −45.8 | −45.3 (P < 0.001d; P = 0.704b) | −51.5 |
| VLDL-C | n = 235 | n = 244 | n = 243 | n = 243 | n = 237 | n = 126 |
| Baseline mean (mg/dL) | 63.3 | 69.8 | 66.9 | 70.5 | 67.9 | 68.1 |
| Final mean (mg/dL) | 35.7 | 38.2 | 26.5 | 36.5 | 27.0 | 31.0 |
| Mean percent change from baseline (%) | −31.9 | −41.0 | −55.8 (P < 0.001a) | −42.1 | −50.6 (P = 0.038b) | −49.1 |
| TC | n = 242 | n = 252 | n = 252 | n = 255 | n = 249 | n = 127 |
| Baseline mean (mg/dL) | 256.2 | 258.2 | 257.9 | 260.0 | 258.3 | 258.1 |
| Final mean (mg/dL | 220.2 | 173.3 | 167.8 | 161.7 | 164.0 | 147.0 |
| Mean percent change from baseline (%) | −13.5 | −32.5 | −34.4 (P = 0.08a) | −37.3 | −35.7 (P = 0.138b) | −42.7 |
| ApoB | n = 239 | n = 248 | n = 252 | n = 252 | n = 244 | n = 123 |
| Baseline mean (mg/dL) | 143.1 | 145.5 | 144.7 | 146.1 | 145.6 | 145.4 |
| Final mean (mg/dL) | 119.7 | 94.8 | 87.6 | 87.0 | 86.8 | 79.2 |
| Mean percent change from baseline (%) | −16.2 | −34.1 | −39.2 (P < 0.001a) | −39.6 | −39.2 (P = 0.729b) | −45.0 |
| hsCRP | n = 241 | n = 249 | n = 252 | n = 254 | n = 246 | n = 125 |
| Baseline median (mg/dL) | 0.28 | 0.27 | 0.35 | 0.27 | 0.31 | 0.29 |
| Mean percent change from baseline (%) | −12.1 | −22.9 | −33.8 (P = 0.013a) | −29.9 | −40.8 (P = 0.01b) | −33.1 |
a
Notes: P-value comparison of rosuvastatin 10 mg to fenofibric acid + rosuvastatin 10 mg;
b
P-value comparison of rosuvastatin 20 mg to fenofibric acid + rosuvastatin mg;
c
P-value comparison of fenofibric acid to fenofibric acid + rosuvastatin 10 mg;
d
P-value comparison of fenofibric acid to fenofibric acid + rosuvastatin 20 mg.
Abbreviations: HDL-C, high-density lipoprotein-cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein-cholesterol; non-HDL-C, non-high-density lipoprotein-cholesterol; VLDL-C, very-low-density lipoprotein-cholesterol; TC, total cholesterol; ApoB, apolipoprotein B; hsCRP, high-sensitivity C-reactive protein.